Press Releases May 13, 2026 09:00 AM

Janet Drysdale to address the 19th Annual Wolfe Research Global Transportation & Industrials Conference on May 21

CN's EVP Janet Drysdale to present at Wolfe Research Transportation & Industrials Conference

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
CNR

Janet Drysdale, Executive VP and Chief Commercial Officer of CN, is scheduled to speak at the 19th Annual Wolfe Research Global Transportation & Industrials Conference on May 21, 2026. The presentation will be webcast live and available for replay, highlighting CN's role in North American rail transportation.

Janet Drysdale to address the 19th Annual Wolfe Research Global Transportation & Industrials Conference on May 21
CNR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Janet Drysdale to address prominent Wolfe Research conference, increasing visibility of CN's operations.
  • CN operates a nearly 20,000-mile rail network connecting key North American economic regions, facilitating trade.
  • The event webcast and replay provide investors and stakeholders direct access to company insights and strategy updates.

MONTREAL, May 13, 2026 (GLOBE NEWSWIRE) -- Janet Drysdale, Executive Vice-President and Chief Commercial Officer of CN (TSX: CNR) (NYSE: CNI), will address the 19th Annual Wolfe Research Global Transportation & Industrials Conference on May 21, 2026, starting at 8:00 a.m. Eastern Time (ET).

CN will provide a live webcast via the Investors section of its website at www.cn.ca/investors. A replay of the webcast will be available following the event.

About CN
CN powers the economy by safely transporting more than 300 million tons of natural resources, manufactured products, and finished goods throughout North America every year for its customers. With its nearly 20,000-mile rail network and related transportation services, CN connects Canada’s Eastern and Western coasts with the U.S. Midwest and the U.S. Gulf Coast, contributing to sustainable trade and the prosperity of the communities in which it operates since 1919.

Contacts: 

MediaInvestment CommunityAshley MichnowskiJamie LockwoodSenior ManagerVice-PresidentMedia RelationsInvestor Relations & Special Projects(438) 596-4329(514) 399-0052

media@cn.cainvestor.relations@cn.ca

Risks

  • The article does not disclose new operating or financial data, limiting immediate impact on investor expectations.
  • Transportation sector sensitive to economic cycles and trade volumes, which could affect CN's future performance.
  • Broader economic or regulatory changes in U.S. and Canada may impact CN's rail operations and profitability.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026